Annovis Bio, Inc.
ANVS
$2.06
-$0.02-0.96%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.11M | 1.27M | 1.74M | 1.70M | 1.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.27M | 6.28M | 6.73M | 4.39M | 7.76M |
| Operating Income | -6.27M | -6.28M | -6.73M | -4.39M | -7.76M |
| Income Before Tax | -6.22M | -5.54M | -5.86M | -12.64M | -5.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.22M | -5.54M | -5.86M | -12.64M | -5.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.22M | -5.54M | -5.86M | -12.64M | -5.02M |
| EBIT | -6.27M | -6.28M | -6.73M | -4.39M | -7.76M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.32 | -0.32 | -0.43 | -0.97 | -0.44 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.27 | -0.61 | -0.28 |
| EPS Diluted | -0.32 | -0.32 | -0.48 | -0.97 | -0.44 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.27 | -0.61 | -0.28 |
| Average Basic Shares Outstanding | 19.49M | 17.43M | 13.79M | 12.98M | 11.31M |
| Average Diluted Shares Outstanding | 19.49M | 17.43M | 13.79M | 12.98M | 11.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |